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In 66 breast cancer biopsies, the expression of the Ca
2+-binding protein S100A4, E-cadherin, a- and b-catenin was examined
by immunohistochemistry, and the results were related to clinical and pathological parameters. High levels of S100A4 were
found to signiﬁcantly correlate with histological grade (P=0.030) and loss of oestrogen receptor (P=0.046), but not to the
time interval between surgery and development of distant metastasis (P=0.51) or to patient survival (P=0.89). Loss of E-
cadherin expression, associated with altered cell–cell adhesion, showed a highly signiﬁcant association to overall survival
(P=0.020) and metastasis-free period (P=0.0052). In multivariate analysis, only lymph node involvement was a more signiﬁcant
predictor of patient demise. No association was found between expression of S100A4 and any single member of the
cadherin–catenin complex, but a trend (P=0.053) towards reduced expression of one or several of these proteins and
S100A4 immunoreactivity was observed. In conclusion, although our results suggest an association between S100A4
expression and an aggressive tumour phenotype, no relationship to overall survival was found. Deregulation of E-cadherin
expression, however, was of high prognostic signiﬁcance.
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Breast cancer is the leading cause of cancer deaths among women
in the Western world, with almost one woman in 11 developing
cancer, and nearly half of these dying from metastatic disease.
Identifying patients likely to develop metastatic spread at an early
stage in disease progression may have important clinical implica-
tions and may affect treatment regimens, and several prognostic
factors are established. Of these are lymph node involvement,
tumour diameter and histological grade considered the most infor-
mative and hence commonly used in the clinical setting. Candidate
molecular markers of breast cancer progression include c-erbB-2,
ER, PgR, p53, integrins and proteases. However, to date none of
these markers have turned out to add considerably to the prognos-
tic signiﬁcance of the clinical and pathological factors mentioned
above (Walker et al, 1997).
The S100 family of Ca
2+-binding proteins comprises 19
members, each member exhibiting a unique expression pattern in
human tissues and exerting different functions (Donato, 2001).
The S100A4 gene, cloned from murine mammary carcinoma cells,
has been shown to be speciﬁcally expressed in cells with high meta-
static capability (Ebralidze et al, 1989), but how S100A4 exerts its
putative metastasis-promoting effects is largely unknown (Barra-
clough, 1998). The S100A4 protein has been found to colocalize
with ﬁlamentous actin (Mandinova et al, 1998) and interact with
nonmuscle myosin (Kriajevska et al, 1994) and nonmuscle tropo-
myosin (Takenaga et al, 1994), and therefore supposed to be
involved in regulating cytoskeletal dynamics. We have previously
shown, using a speciﬁc ribozyme transfected into highly metastatic
S100A4 expressing human osteosarcoma cells, that reduced expres-
sion of S100A4 leads to a nearly complete reversal of the metastatic
phenotype in an animal model (Mælandsmo et al, 1996). Corre-
spondingly, the ribozyme-transfected cells were less motile and
invasive in vitro, possibly due to deregulated expression of matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloprotei-
nases (TIMPs) (Bjornland et al, 1999).
E-cadherin is a member of the cadherin superfamily that
mediates homophilic, calcium-dependent cell–cell adhesion
(Takeichi, 1991). Catenins, comprising at least three molecules,
a-, b- and g-catenin, are cadherin-associated intracellular proteins
linking the cadherins to the actin cytoskeleton (Ozawa et al,
1989). In several types of carcinomas reduced expression or abnor-
mal location of E-cadherin and the catenins have been observed,
and the involvement of the E-cadherin–catenin system in suppres-
sing cancer progression is well established (Bracke et al, 1996;
Hirohashi, 1998; Behrens, 1999).
Recently, prognostic signiﬁcance of S100A4 expression has been
shown in several cancer types (Kimura et al, 2000; Rudland et al,
2000; Yonemura et al, 2000; Ninomiya et al, 2001). Surprisingly,
for stage I and II breast carcinoma patients S100A4 was found to
be the most signiﬁcant predictor of patient survival, also compared
to the well documented clinical and pathological parameters
(Rudland et al, 2000). In other studies, an inverse correlation
between S100A4 and members of the E-cadherin–catenin complex
was revealed in non small cell lung cancer (NSCLC) and gastric
cancer (Kimura et al, 2000; Yonemura et al, 2000). The possible
association between these metastasis-associated proteins has not,
to our knowledge, been studied in tumour biopsies from breast
cancer patients. Moreover, the importance of E-cadherin in breast
cancer is somewhat uncertain, and in different tumour panels it
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www.bjcancer.comhas been found that loss of, as well as sustained, E-cadherin expres-
sion was of prognostic signiﬁcance (Lipponen et al, 1994; Siitonen
et al, 1996; Bukholm et al, 1998; Tan et al, 1999; Gillett et al,
2001).
The main objective of the present study was to study the expres-
sion patterns of S100A4 and E-cadherin in a panel of 66 breast
cancer biopsies and to investigate whether the expression levels
were associated with known tumour variables or patient survival.
MATERIALS AND METHODS
Clinical specimens
Tumour tissue was collected with ethical approval and full
informed consent at primary operation from 66 patients with oper-
able breast cancer at the Norwegian Radium Hospital between 1992
and 1994. The fresh tumour tissue was snap frozen in liquid nitro-
gen and stored at 7708C. The surgical treatment given was either
radical mastectomy (77%) or lumpectomy (23%) with or without
sampling of axillary glands. Patients were assigned to chemother-
apy, hormone therapy or radiation, or a combination of these,
depending on the characteristics of the tumour. The lymph nodes,
when available, were assessed histologically and recorded as
containing or not containing carcinoma cells, and were not
analysed with respect to the number of lymph nodes involved.
Mean age at presentation was 55 years (range 32–80). Tumour
diameter, histological grade, oestrogen and progesterone receptor
status were recorded for all patients. Oestrogen and progesterone
receptor status were measured using a ligand-binding assay (cut-
off value 10 fmol/mg protein) or immunocytochemistry (420%
of the cells showing nuclear staining). An overview of the clinical
and pathological characteristics is summarised in Table 1.
Antibodies
Polyclonal anti-S100A4 antibody was purchased from DAKO,
Glostrup, Denmark and used in dilution of 1:50. Monoclonal
anti-a-catenin (Santa Cruz Biotechnology, Santa Cruz, USA),
anti-b-catenin (Transduction Laboratories, Lexington, USA) and
anti-E-cadherin (Zymed, San Francisco, USA) were all diluted
1:200. The speciﬁcity of the S100A4 antibody is described else-
where (Pedrocchi et al, 1994).
Immunohistochemistry
Tumour tissue was embedded in Tissue-Tek O.C.T. Compound
(Sakura Finetek, Zoeterwoude, The Netherlands), and 5 mm thin
frozen sections were cut consecutively from the tumour samples
and stored air-protected at 7708C. One section from each tissue
sample was H&E-stained and examined for the presence of tumour
tissue. Sections were ﬁxed in acetone, blocked with normal rabbit
serum (monoclonal antibodies) or normal horse serum (polyclonal
antibodies) and incubated with primary antibody for 30 min at
room temperature. For the monoclonal antibodies, antibody bind-
ing was detected using a secondary rabbit anti-mouse antibody
followed by an alkaline phosphatase complex (DAKO, Glostrup,
Denmark). Polyclonal antibody binding was detected using alkaline
phosphatase-conjugated swine anti-rabbit (DAKO, Glostrup,
Denmark) and rabbit anti-swine (ICN, Costa Mesa, USA) immu-
noglobulins. Bound antibody-alkaline phosphatase complex was
visualised using New Fuchsin substrate. Sections were counter-
stained in Mayer’s hematoxylin and mounted in Glycergel
(DAKO, Glostrup, Denmark).
Sections were scored microscopically by two independent obser-
vers. For each sample, at least 100 cells, and usually more than
1000 cells, were analysed. For cases with regions of inhomogeneity
within the same section, the total number of tumour cells was
analysed. The number of immunopositive cells was semiquantita-
tively estimated: negative (7), 0%; borderline positive (+), 1–
5%; moderately positive (++), 5–50%; and strongly positive
(+++), 450% of the carcinoma cells stained. For S100A4 cytoplas-
mic staining was recorded, and for a-catenin, b-catenin and E-
cadherin only membrane staining was regarded as positive. In
addition, staining intensity was recorded for S100A4. The staining
intensities reﬂected the number of immunopositive cells, thus
conducting the analyses using this variable gave no signiﬁcant asso-
ciations not seen using the number of positive cells. Normal breast
epithelium and lymphocytes adjacent to the tumour tissue served
as positive control for the proteins of the cadherin–catenin
complex and S100A4, respectively. Negative controls included
substitution of the primary antibody with an unspeciﬁc antibody
of the same subclass, as well as staining of cell lines previously
known to be negative for S100A4, E-cadherin and the catenins.
Statistical analysis
Follow-up information was obtained from the Norwegian Cancer
Registry, a nation-wide register of all cancer patients, and from
the patient records at the hospital. All data were updated to August
1, 2000, giving a mean follow-up for patients still alive of 79
months. The numbers in each of the four groups were too small
for independent statistical analysis. Therefore, unless otherwise
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Table 1 Clinicopathological parameters
Variable No. of patients % of patients
Age
550 years 28 42
550 years 38 58
Histology
Inﬁltrating ductal 52 79
DCIS 3 4.5
Inﬁltrating lobular 8 12
Others/unknown 3 4.5
Tumour diameter
42.0 cm (T1) 16 24
2.0–5.0 cm (T2) 23 45
45.0 cm (T3) 23 35
Unknown 4 6.0
Histological grade
I8 1 2
II 19 29
III 17 26
Unknown 22 33
Lymph node involvement
Present 27 41
Absent 37 56
Unknown 2 3.0
Stage
I1 4 2 1
II 29 44
III 15 23
IV 6 9.0
Unknown 2 3.0
ER
Positive 23 35
Negative 39 59
Unknown 4 6.0
PgR
Positive 30 45
Negative 32 49
Unknown 4 6.0
Distal metastases
Present 30 45
Absent 36 55
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tumours were grouped as negative, and the moderately and
strongly positive tumours were grouped as positive. The correlation
of immunohistochemical staining of any of the proteins with each
other or other tumour variables was tested using chi-squared tests.
The other tumour variables tested included patient age, tumour
diameter, lymph node status, histological grade and presence of
ER or PgR in the primary tumour. For each of the proteins, asso-
ciation between staining and patient survival or time to
development of distant metastases was tested using Kaplan–Meier
survival plots. Patients dying from other causes than their breast
cancer were excluded from the analysis. Multivariate analysis was
performed using Cox proportional hazards regression model.
Statistical analyses were performed using Statistical Package for
the Social Sciences, version 6.1 (SPSS Inc., Chicago, USA).
RESULTS
Immunohistochemical staining
In normal breast tissue adjacent to the tumour S100A4 protein
expression was detected in a variety of different cell types. The
cytoplasm of smooth muscle cells of the vessel walls, lymphocytes,
macrophages and the intralobular connective tissue were consis-
tently positive, while the interlobular connective tissue showed
no staining for S100A4. Epithelial cells of the ducts and ductules
occasionally showed positive staining, though the majority of these
were not immunoreactive. The staining of normal tissue was not
assessed further, though it was observed that tumours expressing
high amounts of S100A4 protein also showed stronger immuno-
reactivity in the corresponding normal tissue. Tumour cells
displayed a uniform, cytoplasmic staining for S100A4 (Figure 1).
In 22 (35%) cases no immunoreactivity was observed, six (10%)
samples were borderline positive, 16 (26%) samples were moder-
ately positive and 18 (29%) were strongly positive.
Normal breast epithelium showed strong membrane immuno-
reactivity for E-cadherin, a- and b-catenin. In tumour cells, stain-
ing was conﬁned not only to the membrane (Figure 1), but also
present diffusely in the cytoplasm. No immunoreactivity was
observed in the nuclei. Normally functioning cadherin and catenin
molecules are associated with the cell membrane, therefore only
membrane staining was interpreted as positive. A summary of
the immunohistochemical analysis is presented in Table 2.
Correlation of S100A4 protein expression with proteins in
the cadherin–catenin complex
In the chi-square analysis, immunohistochemical staining for
S100A4 was not correlated to expression of E-cadherin, a-o rb-
catenin. However, when the expression of these three interacting
proteins was summarised as one variable, a trend towards reduced
expression of one or several of these proteins and S100A4 immu-
noreactivity was seen (P=0.053). As expected, the proteins in the
cadherin–catenin complex demonstrated a highly signiﬁcant corre-
lation to each other when analysed separately.
Association between molecular markers and
clinical parameters
In contrast to previous reports, in our study S100A4 immuno-
reactivity was not associated with overall survival or time to
metastasis. (Kaplan–Meier survival plot, P=0.89 and P=0.51,
respectively. See Figure 2). Including only the ductal carcinomas
(55 cases) in the analyses, or including the borderline group with-
in the positive samples, did not in any case dramatically affect the
analyses. S100A4 protein expression was signiﬁcantly correlated to
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Figure 1 Top panel: Tumour tissue showing strong immunoreactivity (+++) to the proteins indicated. Note the cytoplasmic staining for S100A4, while
the adhesion molecules show a membranous distribution. Lower panel: Tumour tissue showing no (7) immunoreactivity.
Table 2 Immunohistochemical staining of breast cancer specimens
Variable Negative (7) Borderline positive (+) Moderately positive (++) Strongly positive (+++) ND
a
S100A4 22 (35%) 6 (10%) 16 (26%) 18 (29%) 4
E-cadherin 28 (46%) 5 (8%) 9 (15%) 19 (31%) 5
a-catenin 14 (23%) 5 (8%) 12 (19%) 31 (50%) 4
b-catenin 18 (30%) 6 (10%) 8 (13%) 29 (47%) 5
aND=Not determined
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1281–1286loss of ER (P=0.046) using chi-squared tests. Particularly the
S100A4 negative group showed a clear tendency towards ER
expression, with 20 of 27 (74%) samples positive for ER
compared to 15 of 31 (48%) samples in the S100A4 positive
group. S100A4 immunoreactivity demonstrated a signiﬁcant corre-
lation with high histological grade (P=0.030), with only ﬁve of 22
(23%) of the S100A4 negative tumours described as a grade III
tumour, compared to 12 of 22 (55%) of the S100A4 positive
tumours. S100A4 staining was not correlated to the patients’ ages
at time of presentation, PgR, lymph node involvement or tumour
diameter.
Of the three other molecular markers examined, loss of E-
cadherin membrane staining was associated with poor prognosis
(P=0.020, Figure 2) and a short metastasis-free period
(P=0.0052), while a-o rb-catenin expression did not reveal any
association with these parameters. Reduced expression of one or
more of the examined proteins in the cadherin–catenin complex
showed only a trend (P=0.055) towards shortened survival, and
did not add prognostic information to the established associations
for loss of E-cadherin staining. Of the other tumour variables
tested, lymph node involvement (P=0.0047) and tumour diameter
of more than 5.0 cm (P=0.0017) showed a signiﬁcant association
with shorter patient survival. In contrast, ER and PgR status,
patient age and histological grade were of no prognostic signiﬁ-
cance in this subset of tumour samples. None of the E-cadherin-
associated adhesion molecules tested showed any correlation to
any of the tumour variables above.
Using the Cox regression model, nodal status proved to give the
highest signiﬁcance (P=0.0075), followed by loss of E-cadherin
immunoreactivity (P=0.016) and tumour diameter of more than
5.0 cm (P=0.023). The multivariate analysis is summarised in Table
3.
DISCUSSION
We examined by immunohistochemistry the protein expression of
S100A4, a metastasis-associated protein, in human breast cancer
specimens. In addition, expression of the cell–cell adhesion mole-
cules E-cadherin, a- and b-catenin were investigated, and the
protein levels of these markers were related to clinicopathological
variables and survival data.
Of the 66 breast carcinomas in our tumour material, only 62
were available for analysis of S100A4 immunoreactivity. The
expression differed widely, but positive cells showed a uniform
cytoplasmic staining pattern. Twenty-eight cases (45%) were scored
as negative and 34 cases (55%) as positive. In contrast to the recent
report by Rudland et al (2000), we did not ﬁnd any association
between the expression levels of S100A4 and clinical outcome. In
their study, S100A4 was the most signiﬁcant predictor of patient
survival in a panel of 349 stage I and II breast cancer patients.
Several possible explanations for this inconsistency might exist, of
which the most likely is that our panel includes fewer samples
(n=62), and that we also included stage III and IV breast cancer
patients in the study. One could speculate that the prognostic value
of S100A4 might be more questionable in the more advanced cases.
When excluding these patients, however, we got similar results,
arguing against this being the reason for the different results in
the two studies. It should be noted that the follow-up period in
our study is relatively short, with a mean of 79 months for patients
still alive. Moreover, we investigated snap-frozen, acetone-ﬁxed
tumour biopsies, while Rudland et al (2000) examined archival
formalin-ﬁxed, parafﬁn-embedded specimens. Such differences in
preservation and ﬁxation could possibly affect the results, although
both we and others have previously obtained consistent results with
anti-S100A4 antibodies regardless of storage conditions or ﬁxation
method (Rudland et al, 2000). Taken together, our results seem to
question the prognostic value of S100A4 in breast cancer patients,
and further investigations are warranted to elucidate the impor-
tance of this S100 protein as a prognostic factor.
In the present study, we included within an 18-month period all
breast cancer patients undergoing surgery at our hospital, from
whom it was possible to obtain a biopsy for research purposes.
This explains the overrepresentation of patients with large
tumours. As can be seen in the staging and clinical data presented
in Table 1, biopsies from patients with stage I breast cancers are
rather few compared to a normal stage distribution. Nevertheless,
the fact that known prognostic parameters such as nodal status
and tumour diameter were signiﬁcantly associated with patient
survival ensures the quality of our panel of tumour material.
Despite the lack of relation to survival, we found a signiﬁcant
association between high S100A4 protein expression and histologi-
cal grade III (P=0.030), as well as an inverse correlation to
expression of oestrogen receptor (P=0.046). These ﬁndings indicate
a relation between S100A4 and an aggressive phenotype, as both
loss of ER and high histological grade are known indicators of
aggressive disease. The observed inverse correlation between
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Figure 2 Kaplan–Meier survival curves demonstrating the relationship
between patient survival and protein expression of S100A4 (a) and (b)
E-cadherin.
Table 3 Cox regression analysis of overall survival for breast carcinomas
(n=62)
Overall survival
Variable p RR 95% CI
Lymph node involvement 0.0075 5.58 1.58–19.7
E-cadherin 0.016 3.38 1.25–9.10
Tumour diameter 0.023 2.18 1.11–4.28
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British Journal of Cancer (2002) 87(11), 1281–1286 ã 2002 Cancer Research UKS100A4 and ER is in agreement with previous expression studies
performed on human breast cancer specimens (Albertazzi et al,
1998; Nikitenko et al, 2000). Additionally, transfection of mts1
(mouse S100A4) into human MCF-7 cells resulted in oestrogen-
independent growth in vivo and deregulation of oestrogen-respon-
sive genes (Grigorian et al, 1996).
A signiﬁcant association was seen between loss of E-cadherin
immunoreactivity at the cell membrane and both patient survival
and metastasis-free period. In addition, loss of E-cadherin staining
proved to be an independent prognostic factor using multivariate
analyses, as did lymph node involvement and tumour diameter.
This ﬁnding is in concordance with most previous studies (Lippo-
nen et al, 1994; Siitonen et al, 1996), and strengthens the
hypothesis of E-cadherin being a metastasis-suppressing molecule
and a prognostic indicator in breast cancer. Two recent studies
have highlighted the role of preserved E-cadherin membrane stain-
ing as an indicator of early patient demise (Gillett et al, 2001; Tan
et al, 1999), and re-expression of E-cadherin also occurs in meta-
static tumours (Bukholm et al, 2000). These reports indicate that
retained adhesive ability may promote invasion, colony formation
and growth in a secondary organ. Based upon our results, one
might speculate that local invasion and extravasation is promoted
through loss of E-cadherin function, and that the adhesive proper-
ties required for formation of metastases could possibly be regained
through re-expression of E-cadherin or expression of other adhe-
sion molecules. Additionally, in E-cadherin-negative tumours
invasion could be promoted through ectodomain shedding (Noe
et al, 2001). The HECD-1 antibody used here recognises the extra-
cellular domain of human E-cadherin, thus E-cadherin negative
tumours may have a proteolytically cleaved E-cadherin, lacking
the shedded ectodomain. Hence, in these tumours invasion is
possibly promoted through processes distinct from the mere loss
of cell–cell adhesion.
An inverse correlation between S100A4 and members of the
cadherin–catenin complex has recently been shown in gastric
cancer and NSCLC (Kimura et al, 2000; Yonemura et al, 2000),
and S100A4 and E-cadherin have been reported to be inversely
regulated in a murine mammary carcinoma cell line (Keirsebilck
et al, 1998). We did, however, not ﬁnd any correlation between
S100A4 immunoreactivity and expression of E-cadherin, a-o rb-
catenin, but a trend towards reduced expression of one or several
of the proteins in the cadherin–catenin complex and S100A4
could be observed (P=0.053). The discrepancy with earlier results
is possibly a reﬂection of different biological behaviour of tumours
of different origin. Furthermore, the immunohistochemical evalua-
tion may be critical, as we, in contrast to the study by Kimura et al
(2000), have interpreted cytoplasmic staining of cadherins and
catenins as negative because normally functioning adhesion mole-
cules are located in association with the cell membrane.
Immunoreactivity to proteins in the cadherin–catenin complex
was in our material observed at the cell membrane in both tumour
and normal epithelial cells, as well as in the cytoplasm of some
tumour cells, while no staining was observed in the nuclei. b-cate-
nin is known to accumulate in the cytoplasm and nucleus of
colorectal cancer cells through mutations in APC or b-catenin itself
(Morin et al, 1997), and thereby function as a transcriptional acti-
vator when complexed with members of the Tcf family of DNA-
binding proteins (Behrens et al, 1996). Nuclear accumulation of
b-catenin has recently also been shown in breast cancer (Lin et
al, 2000), while nuclear localisation of a-catenin has not been
reported. In our panel of dry-frozen breast cancer biopsies, we
did not detect any b-catenin in the nuclei. This is in agreement
with Munne et al (1999), who, using the same antibody as in
the present study, detected nuclear b-catenin in formalin-ﬁxed,
parafﬁn-embedded colorectal cancer sections, but not in adjacent
frozen sections from the same tumour tissue. The reasons for this
phenomenon are at present unknown, but it indicates that the
COOH-terminal part of b-catenin is masked in frozen specimens,
possibly due to interaction with other molecules. That b-catenin
might be localised to the nucleus in some of the examined biopsies
could therefore not be ruled out.
In conclusion, we have shown that loss of E-cadherin immuno-
reactivity was signiﬁcantly associated with patient survival and
tumour progression in the examined breast cancer specimens.
Neither E-cadherin nor the catenins were associated with S100A4
expression, while a signiﬁcant correlation was found between high
levels of S100A4 and both histological grade III and loss of ER.
Despite the association between aggressive tumours and S100A4
expression, the protein level was not a prognostic factor in this
panel of breast cancer samples, and further studies are warranted
to elucidate the prognostic role of S100A4.
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